Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Europe Sun.
Press releases published on April 25, 2025
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
GlobeNewswire
·
April 25, 2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 25 April 2025 at 17.20 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a …
CHMP recommends EU approval for Duvyzat to treat Duchenne muscular dystrophy
GlobeNewswire
·
April 25, 2025
Recommendation is based on Phase 3 EPIDYS trial data that demonstrated Duvyzat (givinostat) provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular dystrophy (DMD) If approved by the European Commission, …
Heineken® Joins Forces with Joe Jonas and Global Influencers to Help Tackle Digital Overload and Get Social ‘Off Socials’
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- GRAMMY® Award-nominated singer, songwriter, actor and producer, Joe Jonas teamed up with Dude With Sign (Seth Phillips) in New York City last night to create their latest social post - only this time they did so …
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
GlobeNewswire
·
April 25, 2025
Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical …
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
GlobeNewswire
·
April 25, 2025
In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational study Company remains confident in continuing to pursue evorpacept in …
Best Testosterone Booster For Erectile Dysfunction (ED) And Muscle Building 2025: Top T Booster Supplement For Men Over 40 And 50 – By Testo Prime
GlobeNewswire
·
April 25, 2025
Glasgow, Scotland, April 25, 2025 (GLOBE NEWSWIRE) -- According to Harvard Health Publishing and Mayo Clinic, testosterone levels in men start decreasing after the age of 30. Changes are slow and research shows a gradual decline of 1% every year. Gradual …
Decisions taken by Suominen Corporation’s Annual General Meeting and the Board of Directors
GlobeNewswire
·
April 25, 2025
Suominen Corporation's Stock Exchange Release on April 25, 2025 at 3:45 p.m. (EEST) The Annual General Meeting (AGM) of Suominen Corporation was held today on April 25, 2025 in Helsinki, Finland. The AGM adopted the Financial Statements for 2024 and …
Suominen Oyj:n varsinaisen yhtiökokouksen ja hallituksen järjestäytymiskokouksen päätökset
GlobeNewswire
·
April 25, 2025
Suominen Oyj:n pörssitiedote 25.4.2025 klo 15.45 Suominen Oyj:n varsinainen yhtiökokous pidettiin tänään 25.4.2025 Helsingissä. Yhtiökokous vahvisti vuoden 2024 tilinpäätöksen sekä myönsi vastuuvapauden hallituksen jäsenille ja toimitusjohtajalle …
Rush Factory Oyj: Osakevaihdon odotetaan toteutuvan arviolta 28.4.2025 ja kaupankäynnin alkavan arviolta 29.4.2025; päivitys hallituksen kokoonpanoon osakevaihdon jälkeen
GlobeNewswire
·
April 25, 2025
Rush Factory Oyj 25.4.2025 klo 15.30 EI JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI YHDYSVALTOIHIN, KANADAAN, UUTEEN-SEELANTIIN, AUSTRALIAAN, JAPANIIN, HONGKONGIIN, SINGAPOREEN TAI ETELÄ-AFRIKKAAN TAI MIHINKÄÄN MUUHUN VALTIOON, JOSSA …
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
GlobeNewswire
·
April 25, 2025
WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four …
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
GlobeNewswire
·
April 25, 2025
TARPON SPRINGS, Fla., April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a …
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
GlobeNewswire
·
April 25, 2025
Vancouver, Canada, April 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Spryker von RetailTech Breakthrough als „E-Commerce-Lösung des Jahres 2025“ ausgezeichnet
GlobeNewswire
·
April 25, 2025
BERLIN und NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Spyker, die führende Composable-Commerce-Plattform für anspruchsvolle Anwendungsfälle im B2B-Commerce, Enterprise Marketplaces und IoT Commerce, hat heute bekanntgegeben, dass das Unternehmen im …
Spryker est nommée « Solution e-commerce de l’année » 2025 par RetailTech Breakthrough
GlobeNewswire
·
April 25, 2025
BERLIN et NEW YORK, 25 avr. 2025 (GLOBE NEWSWIRE) -- Spryker, la principale plateforme de commerce modulaire pour les cas d’utilisation sophistiqués autour du B2B Commerce, des Enterprise Marketplaces et de l’IoT Commerce, a annoncé aujourd’hui avoir reçu …
Bitcoin has skyrocketed recently – SIX MINING provides you with stable passive income
GlobeNewswire
·
April 25, 2025
London, UK, April 25, 2025 (GLOBE NEWSWIRE) -- London, UK Apr 24, 2025 (Copper) Affected by the latest trade policy of US President Donald Trump, the global market is volatile, but cryptocurrencies are rising against the trend - Bitcoin has broken through …
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based …
Best Online Casinos Canada: Why 7Bit Casino Is Ranked As Top Canadian Online Casino
GlobeNewswire
·
April 25, 2025
PORTLAND, Ore., April 25, 2025 (GLOBE NEWSWIRE) -- Whether you are looking for luck-based games like slots or skill-based games like poker, 7Bit Casino delivers the best. In this review, we’ll examine its features, including its bonus offers, game …
Echo Launches Real Unique Tokenomics with Real Yield in USDC
GlobeNewswire
·
April 25, 2025
Douglas, Isle of Man, April 25, 2025 (GLOBE NEWSWIRE) -- Echo is about to launch a digital asset that intersects trading income with blockchain openness. The echo token, set to go live on May 15th, has a long list of promises for Web3 fans. The token’s …
BPGbio Highlights Groundbreaking Data on BPM31510 for Mitochondrial Diseases at the Inaugural Mitochondrial Transplantation and Next Generation Therapeutics Conference
GlobeNewswire
·
April 25, 2025
BOSTON, April 25, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, today announced a poster presentation at the inaugural Mitochondrial …
VEON Files its 2024 Annual Report on Form 20-F
GlobeNewswire
·
April 25, 2025
Dubai, April 25, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (‘VEON’ or the ‘Company’), today announces that it has filed its Annual Report on Form 20-F for the year ended December 31, 2024 (the "2024 20-F") with the U.S. Securities and …